Delivery Order SPE2DB20D2014-SPE2DB25FC97P
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin, a pharmaceutical product used in diabetes management. The contract, awarded on August 22, 2025, carries a ceiling value of $2,439.56 with a firm fixed-price structure and an ultimate completion date of August 25, 2025. This non-competitive delivery order represents a relatively small-value transaction typical of routine pharmaceutical replenishment under the...
- The Defense Logistics Agency awarded a $1,968.89 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lantus SoloStar 100 Unit/ML insulin in 3 mL quantities. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 5, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Lantus SoloStar insulin (100 unit/mL, 3mL formulation) with a ceiling value of $1,022.80. This is a firm fixed-price delivery order issued without set-aside designation, indicating competitive award to the vendor. The contract is to be completed by August 21, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin in 3ml quantities. This firm fixed price, competitively awarded contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single transaction executed...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,928.88 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin in 3 mL quantities. The contract is a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was awarded on August 14, 2025. This award carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order valued at $1,889.55 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Lantus SoloStar 100 Unit/mL insulin in 3 mL cartridges. This firm fixed-price delivery order, which is non-competitive set-aside, is scheduled for completion by September 4, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction supporting...
- This delivery order, awarded July 25, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, provides 1 million units of Lantus SoloStar 100 Unit/ML 3ML insulin at a ceiling value of $1,429.34. The order, which is non-set-aside and competitively awarded, is scheduled for completion by July 28, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency has awarded a delivery order valued at $1,965.00 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin, with a completion date of August 21, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania, where the company is headquartered. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Lantus SoloStar insulin 100 unit/mL in 3 mL pens. This non-set-aside, competitively awarded contract carries a ceiling value of $2,171.76 with firm fixed pricing and an ultimate completion date of August 4, 2025. The pharmaceutical distributor will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin on August 5, 2025, with completion scheduled for August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC97PDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Lantus SoloStar 100 Unit/ML in 3ML quantities, with a ceiling value of $11,936.98. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive $999,999,999.00 IDC with DLA Troop Support Medical, designated as SPE2DX and running through December 2026. This prime contract vehicle enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current delivery order for Lantus SoloStar, an insulin therapy medication for diabetes management, exemplifies the company's role in fulfilling specialized pharmaceutical needs across the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.9k | 9/11/25 |